RECE.F Stock Overview
A biotechnology company, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United States, and the United Kingdom.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Recce Pharmaceuticals Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.60 |
| 52 Week High | AU$0.60 |
| 52 Week Low | AU$0.55 |
| Beta | 1.13 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| RECE.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | 1.7% |
| 1Y | n/a | 21.6% | 23.7% |
Return vs Industry: Insufficient data to determine how RECE.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how RECE.F performed against the US Market.
Price Volatility
| RECE.F volatility | |
|---|---|
| RECE.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: RECE.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine RECE.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | James Graham | www.recce.com.au |
Recce Pharmaceuticals Ltd, a biotechnology company, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company’s lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotic formulated for oral use.
Recce Pharmaceuticals Ltd Fundamentals Summary
| RECE.F fundamental statistics | |
|---|---|
| Market cap | US$65.42m |
| Earnings (TTM) | -US$7.64m |
| Revenue (TTM) | US$4.56m |
14.4x
P/S Ratio-8.6x
P/E RatioIs RECE.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RECE.F income statement (TTM) | |
|---|---|
| Revenue | AU$6.75m |
| Cost of Revenue | AU$8.01m |
| Gross Profit | -AU$1.26m |
| Other Expenses | AU$10.05m |
| Earnings | -AU$11.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.055 |
| Gross Margin | -18.73% |
| Net Profit Margin | -167.74% |
| Debt/Equity Ratio | 418.1% |
How did RECE.F perform over the long term?
See historical performance and comparison